Anti-CD3 epsilon antibodies and methods of use thereof

Patent metadata

Field	Value
Publication number	US-11203646-B2
Application number	US-201916353916-A
Country	US
Kind code	B2
Filing date	Mar 14, 2019
Priority date	Mar 14, 2018
Publication date	Dec 21, 2021
Grant date	Dec 21, 2021

Abstract

The disclosure relates to monoclonal antibodies and antigen binding fragments, variants, multimeric versions, or bispecifics thereof that specifically bind CD3 epsilon (CD3ε), as well as methods of making and using these anti-CD3ε antibodies and antigen binding fragments thereof in a variety of therapeutic, diagnostic and prophylactic indications.

First claim

What is claimed is:

1. An antibody that specifically binds CD3ε comprising a heavy chain variable region comprising:
a) a variable heavy chain complementarity determining region 1 (CDRH1) comprising the amino acid sequence of GFTFNTYA (SEQ ID NO: 3);

b) a variable heavy chain complementarity determining region 2 (CDRH2) comprising the amino acid sequence of IRSKYNNYAT (SEQ ID NO: 4); and
c) variable heavy chain complementarity determining region 3 (CDRH3) comprising the amino acid sequence of VRHGNFGNSYVSWFAY (SEQ ID NO: 5); and
a light chain variable region comprising:

d) a variable light chain complementarity determining region 1 (CDRL1) comprising the amino acid sequence of TGAVTTSNY (SEQ ID NO: 11);
e) a variable light chain complementarity determining region 2 (CDRL2) comprising the amino acid sequence of GTN (SEQ ID NO: 12); and
f) a variable light chain complementarity determining region 3 (CDRL3) comprising the amino acid sequence selected from the group consisting of ALWYANRWV (SEQ ID NO: 13), ALWYKGYWV (SEQ ID NO: 14), ALWYDGTWV (SEQ ID NO: 15), ALWYDGKWV (SEQ ID NO: 16), ALWYDGWWV (SEQ ID NO: 17), ALWYKQRWV (SEQ ID NO: 18) and ALWYNQHWV (SEQ ID NO: 19).

2. The antibody of claim 1 , wherein the variable heavy chain region comprises a hIGHV3-73 framework region.

3. The antibody of claim 1 , wherein the variable light chain region comprises a hIGLV7-46 framework region.

4. The antibody of claim 1 , wherein the heavy chain variable region comprises an amino acid sequence of SEQ ID NO: 6 and the light chain variable region comprises an amino acid sequence of SEQ ID NO: 29, 31, 33, 35, 37, 39 or 41.

5. The antibody of claim 4 , wherein the heavy chain variable region comprises an amino acid sequence of SEQ ID NO: 6 and the light chain variable region comprises an amino acid sequence of SEQ ID NO: 39.

6. The antibody of claim 1 , wherein the CD3ε is human CD3ε or cynomolgus monkey CD3ε.

7. The antibody of claim 1 , wherein the antibody is an antigen binding fragment thereof, and wherein the antigen binding fragment is a single chain antibody (scAb), a Fab, a Fab′, a F(ab)2, a F(ab′) 2 , a single chain variable fragment (scFv), a Fv, or a scFv-Fc fragment.

8. The antibody of claim 1 , wherein the antibody is a chimeric antibody or a humanized antibody.

9. The antibody of claim 1 , wherein the antibody is an IgG isotype.

10. The antibody of claim 1 , wherein the antibody is an IgG1 isotype.

11. The antibody of claim 1 , wherein the antibody comprises two copies of a single heavy chain polypeptide and a first light chain and a second light chain, wherein the first and the second light chains are different.

12. The antibody of claim 11 , wherein at least a portion of the first light chain is of the Kappa type and at least a portion of the second light chain is of the Lambda type.

13. The antibody of claim 12 , wherein the first light chain comprises at least a Kappa constant region.

14. The antibody of claim 13 , wherein the second light chain comprises at least a Lambda constant region.

15. The antibody of claim 14 , wherein the second light chain further comprises a Lambda variable region.

16. The antibody of claim 14 , wherein the second light chain further comprises a Kappa variable region.

17. The antibody of claim 11 , wherein the first light chain comprises a Kappa constant region and a Kappa variable region, and wherein the second light chain comprises a Lambda constant region and a Lambda variable region.

18. A pharmaceutical composition comprising the antibody of claim 1 .

19. A method of treating and/or delaying the progression of a cancer, comprising administering to a subject in need thereof the pharmaceutical composition of claim 18 .

20. The method of claim 19 , wherein the cancer is leukemia, lymphoma, breast cancer, colon cancer, ovarian cancer, bladder cancer, prostate cancer, glioma, lung cancer, bronchial cancer, colorectal cancer, pancreatic cancer, esophageal cancer, liver cancer, urinary cancer, kidney cancer, pelvis cancer, oral cavity cancer, pharynx cancer, uterine corpus cancer, or melanoma.

21. A method of T-cell retargeting comprising administering to a subject in need thereof the pharmaceutical composition of claim 18 .

22. The antibody of claim 1 , wherein
i) the CDRH1 comprises the amino acid sequence of SEQ ID NO: 3; the CDRH2 comprises the amino acid sequence of SEQ ID NO: 4; the CDRH3 comprises the amino acid sequence of SEQ ID NO: 5; the CDRL1 comprises the amino acid sequence of SEQ ID NO: 11; the CDRL2 comprises the amino acid sequence of SEQ ID NO: 12; and the CDRL3 comprises the amino acid sequence of SEQ ID NO: 18;
ii) the CDRH1 comprises the amino acid sequence of SEQ ID NO: 3; the CDRH2 comprises the amino acid sequence of SEQ ID NO: 4; the CDRH3 comprises the amino acid sequence of SEQ ID NO: 5; the CDRL1 comprises the amino acid sequence of SEQ ID NO: 11; the CDRL2 comprises the amino acid sequence of SEQ ID NO: 12; and the CDRL3 comprises the amino acid sequence of SEQ ID NO: 13;
iii) the CDRH1 comprises the amino acid sequence of SEQ ID NO: 3; the CDRH2 comprises the amino acid sequence of SEQ ID NO: 4; the CDRH3 comprises the amino acid sequence of SEQ ID NO: 5; the CDRL1 comprises the amino acid sequence of SEQ ID NO: 11; the CDRL2 comprises the amino acid sequence of SEQ ID NO: 12; and the CDRL3 comprises the amino acid sequence of SEQ ID NO: 14;
iv) the CDRH1 comprises the amino acid sequence of SEQ ID NO: 3; the CDRH2 comprises the amino acid sequence of SEQ ID NO: 4; the CDRH3 comprises the amino acid sequence of SEQ ID NO: 5; the CDRL1 comprises the amino acid sequence of SEQ ID NO: 11; the CDRL2 comprises the amino acid sequence of SEQ ID NO: 12; and the CDRL3 comprises the amino acid sequence of SEQ ID NO: 15;
v) the CDRH1 comprises the amino acid sequence of SEQ ID NO: 3; the CDRH2 comprises the amino acid sequence of SEQ ID NO: 4; the CDRH3 comprises the amino acid sequence of SEQ ID NO: 5; the CDRL1 comprises the amino acid sequence of SEQ ID NO: 11; the CDRL2 comprises the amino acid sequence of SEQ ID NO: 12; and the CDRL3 comprises the amino acid sequence of SEQ ID NO: 16;
vi) the CDRH1 comprises the amino acid sequence of SEQ ID NO: 3; the CDRH2 comprises the amino acid sequence of SEQ ID NO: 4; the CDRH3 comprises the amino acid sequence of SEQ ID NO: 5; the CDRL1 comprises the amino acid sequence of SEQ ID NO: 11; the CDRL2 comprises the amino acid sequence of SEQ ID NO: 12; and the CDRL3 comprises the amino acid sequence of SEQ ID NO: 17; or
vii) the CDRH1 comprises the amino acid sequence of SEQ ID NO: 3; the CDRH2 comprises the amino acid sequence of SEQ ID NO: 4; the CDRH3 comprises the amino acid sequence of SEQ ID NO: 5; the CDRL1 comprises the amino acid sequence of SEQ ID NO: 11; the CDRL2 comprises the amino acid sequence of SEQ ID NO: 12; and the CDRL3 comprises the amino acid sequence of SEQ ID NO: 19.

23. The antibody of claim 22 , wherein the CDRH1 comprises the amino acid sequence of SEQ ID NO: 3; the CDRH2 comprises the amino acid sequence of SEQ ID NO: 4; the CDRH3 comprises the amino acid sequence of SEQ ID NO: 5; the CDRL1 comprises the amino acid sequence of SEQ ID NO: 11; the CDRL2 comprises the amino acid sequence of SEQ ID NO: 12;
and the CDRL3 comprises the amino acid sequence of SEQ ID NO: 18.

24. The antibody of claim 1 , wherein the antibody is a monoclonal antibody.

Assignees

• Novimmune Sa

Inventors

• Fischer Nicolas
• Magistrelli Giovanni
• Gueneau Franck
• Ravn Ulla

Classifications

• A61K2039/505

  comprising antibodies · CPC title

• C07K2317/565

  Complementarity determining region [CDR] · CPC title

• C07K2317/55

  Fab or Fab' · CPC title

• C07K2317/54

  F(ab')2 · CPC title

• C07K2317/33

  Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity · CPC title